Magforce AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Edison Investment Research
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
MagForce AG Comments on FY 2013 Guidance
MagForce AG announced that the Company cannot be sure whether increasing revenues can be realized in the fiscal year 2013, whereby the Company expects to generate an increasing net loss from operating activities as compared to the fiscal year 2012 as part of its roll-out plan. This will mainly be due to the start of the clinical post-marketing study and preparations for market entry in additional countries. This corresponds to the objectives of the series of measures passed in the fiscal year 2012, the related restructuring of the Company and the focus on strategically important value drivers.
Latest Key Developments in Biotechnology
- BioSpecifics Technologies Corp announces positive data from Phase 2a study of CCH for treatment of Cellulite
- OncoGenex Pharmaceuticals Inc announces update on phase 3 ENSPIRIT trial evaluating Custirsen in advanced non-small cell lung cancer
- Galena Biopharma appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer
- NanoRepro AG confirms FY 2014 revenue outlook
- Share this
- Digg this